ArticleFrontiers in nutrition2026
Alhagi honey polysaccharide ameliorates carbon tetrachloride-induced liver fibrosis via modulating the gut microbiota-liver metabolism axis.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Liver fibrosis (LF) is a progressive injury that frequently advances to cirrhosis and hepatocellular carcinoma, yet effective intervention strategies remain limited. Alhagi honey polysaccharide (AHPN), a bioactive macromolecule with a molecular weight of 9.35 × 10ł Da primarily composed of mannose (29.384%), glucose (41.804%), and galactose (28.810%), represents a promising candidate for antifibrotic therapy. Methods: This study established a carbon tetrachloride (CCl Results: AHPN administration significantly attenuated hepatic injury, reduced collagen deposition, and suppressed fibrosis progression by inhibiting TGF-β1/Smad3 signaling and hepatic stellate cell activation, accompanied by restored liver function. Mechanistically, AHPN activated the Nrf2/HO-1 pathway to alleviate oxidative stress, decreased serum levels of pro-inflammatory cytokines (IL-6, IL-1β, TNF-α), and downregulated fibrosis-related markers (α-SMA, collagen I, LN, PCIII, IV-C). Notably, 16S rDNA sequencing revealed that AHPN enriched beneficial gut bacteria including Conclusion: These findings indicate that AHPN ameliorates CCl
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.